Incidence, risk factors, and outcomes for sepsis-associated delirium in patients with mechanical ventilation: A sub-analysis of a multicenter randomized controlled trial

J Crit Care. 2020 Apr:56:140-144. doi: 10.1016/j.jcrc.2019.12.018. Epub 2019 Dec 24.

Abstract

Purpose: This study aimed to investigate incidence, risk factors, and outcomes for sepsis-associated delirium (SAD) in mechanically ventilated patients.

Materials and methods: We performed a retrospective post-hoc analysis of the DExmedetomidine for Sepsis in Intensive care unit Randomized Evaluation (DESIRE) trial. Outcomes included 28-day mortality, ventilator-free days, length of ICU stay, self-extubation, and re-intubation. Multivariable analysis was performed to identify variables independently associated with SAD.

Results: We retrospectively divided the patients into two groups: delirium group (n = 89) and non-delirium group (n = 98). There were no significant differences between the groups in 28-day mortality, self-extubation, and re-intubation. The number of ventilator-free days was significantly less in the delirium vs. non-delirium group (17 vs. 22 days, p = .006), and the length of ICU stay was significantly longer in the delirium group (10 vs. 5 days, p = .04). Multivariable analyses revealed that emergency surgery, more doses of midazolam, and fentanyl were independent predictors for SAD.

Conclusions: SAD was associated with a less number of ventilator-free days and longer length of ICU stay. Emergency surgery, more doses of midazolam, and fentanyl may be independent risk factors for SAD in mechanically ventilated patients with sepsis.

Keywords: Doses of sedatives and analgesics; Mechanically ventilated patients; Risk factors; Sepsis-associated delirium.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Critical Care
  • Delirium / complications*
  • Delirium / epidemiology*
  • Female
  • Fentanyl / adverse effects
  • Fentanyl / therapeutic use
  • Hospital Mortality
  • Humans
  • Hypnotics and Sedatives
  • Incidence
  • Intensive Care Units
  • Length of Stay
  • Male
  • Midazolam / adverse effects
  • Midazolam / therapeutic use
  • Middle Aged
  • Respiration, Artificial*
  • Retrospective Studies
  • Risk Factors
  • Sepsis / complications*
  • Sepsis / epidemiology*
  • Sepsis-Associated Encephalopathy / chemically induced*
  • Sepsis-Associated Encephalopathy / epidemiology*

Substances

  • Hypnotics and Sedatives
  • Midazolam
  • Fentanyl